PBP2101

PBP2101 is a biosimilar monoclonal antibody being developed by Prestige Biopharma, a Singapore-based biopharmaceutical company. It is designed as a biosimilar to nivolumab (marketed as Opdivo), targeting the Programmed cell death protein 1 (PD-1) receptor. As a PD-1 inhibitor, it works by blocking the PD-1 pathway to enhance the immune system's ability to recognize and eliminate cancer cells. The drug is intended for the treatment of various solid tumors and is currently in the preclinical or discovery stage of development. PBP2101 is part of a broader portfolio of checkpoint inhibitor biosimilars being developed by the company, which also includes biosimilars for pembrolizumab and ipilimumab.

Other names

nivolumab biosimilar